Abstract
Vaccine breakthrough SARS-CoV-2 infection has been monitored in 3720 healthcare workers receiving 2 doses of BNT162b2. SARS-CoV-2 infection is detected in 33 subjects, with a 100-day cumulative incidence of 0.93%. Vaccine protection against acquisition of SARS-CoV-2 infection is 83% (95%CI: 58-93%) in the overall population and 93% (95%CI: 69-99%) in SARS-CoV-2-experienced subjects, when compared with a non-vaccinated control group from the same Institution, in which SARS-CoV-2 infection occurs in 20/346 subjects (100-day cumulative incidence: 5.78%). The infection is symptomatic in 16 (48%) vaccinated subjects vs 17 (85%) controls (p=0.001). All analyzed patients, in whom the amount of viral RNA was sufficient for genome sequencing, results infected by the alpha variant. Antibody and T-cell responses are not reduced in subjects with breakthrough infection. Evidence of virus transmission, determined by contact tracing, is observed in two (6.1%) cases. This real-world data support the protective effect of BNT162b2 vaccine. A triple antigenic exposure, such as two-dose vaccine schedule in experienced subjects, may confer a higher protection.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by Fondazione Cariplo [grant CoVIM, no. 2020-1374] and Ministero della Salute, Ricerca Finalizzata [grants no. COVID-2020-12371760 and COVID-2020-12371817]. AP and FB have received funding from the European Union Horizon 2020 research and innovation programme under grant agreement No 101003650.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Study procedures were approved by Fondazione IRCCS Policlinico San Matteo. Ethics approval was provided by "Comitato Etico Area Pavia" (Procedures no. 20200101361 and 2021000232).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
In agreement with the suggestions of the reviewers we modified the control group. Presently, the control group includes 346 healthcare workers of the same Institution, that did not receive the vaccination during the study period (January-May 2021). We also added a Figure to better describe the study population by stage.
We added more data to better compare the level of severity of the infections in the two study groups. In more detail, we evaluated the type of symptoms and their frequency in SARS CoV2 vaccinated and non-vaccinated subjects, showing the data in a specific table (Table 1). We removed the pie chart. We compared also the frequency of hospitalization, in the group of the breakthrough cases nobody needed hospitalization while in the group of non-vaccinated 2 subjects with pneumonia required hospitalization and one was transferred to Intensive Care Unit due to worsening of symptoms.
Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.
